Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 3, 2014, 112 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $402.00 to $128,403,039.00.

Highlighted Stocks Traded by Insiders:

bluebird bio (BLUE) - FREE Research Report

Leschly Nick, who is President and CEO at bluebird bio, sold 4,834 shares at $39.70 on Dec. 3, 2014. Following this transaction, the President and CEO owned 245,653 shares meaning that the stake was reduced by 1.93% with the 4,834-share transaction.

The shares most recently traded at $42.70, up $3.00, or 7.02% since the insider transaction. Historical insider transactions for bluebird bio go as follows:

  • 4-Week # shares bought: 2,941
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 2,941
  • 12-Week # shares sold: 191,900
  • 24-Week # shares bought: 2,941
  • 24-Week # shares sold: 249,558

The average volume for bluebird bio has been 409,500 shares per day over the past 30 days. Bluebird bio has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 96.19% year-to-date as of the close of trading on Tuesday.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. Currently, there are 5 analysts who rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BLUE - FREE

TheStreet Quant Ratings

TheStreet Recommends

rates bluebird bio as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full

bluebird bio Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Maples Kirk R, who is SVP, Program Management at Anacor Pharmaceuticals, sold 600 shares at $33.38 on Dec. 3, 2014. Following this transaction, the SVP, Program Management owned 4,800 shares meaning that the stake was reduced by 11.11% with the 600-share transaction.

The shares most recently traded at $35.00, up $1.62, or 4.64% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 600
  • 12-Week # shares sold: 1,200
  • 24-Week # shares sold: 15,961

The average volume for Anacor Pharmaceuticals has been 555,900 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are up 98.93% year-to-date as of the close of trading on Tuesday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company has a P/E ratio of 22.9. Currently, there are 3 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings

rates Anacor Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full

Anacor Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

First Merchants (FRME) - FREE Research Report

Sherman Patrick A, who is Director at First Merchants, bought 23 shares at $21.74 on Dec. 3, 2014. Following this transaction, the Director owned 27,078 shares meaning that the stake was boosted by 0.09% with the 23-share transaction.

Lehman Gary, who is Director at First Merchants, bought 77 shares at $21.74 on Dec. 3, 2014. Following this transaction, the Director owned 22,340 shares meaning that the stake was boosted by 0.34% with the 77-share transaction.

The shares most recently traded at $21.88, up $0.14, or 0.65% since the insider transaction. Historical insider transactions for First Merchants go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,473
  • 12-Week # shares bought: 2,204
  • 12-Week # shares sold: 2,473
  • 24-Week # shares bought: 2,576
  • 24-Week # shares sold: 2,473

The average volume for First Merchants has been 95,600 shares per day over the past 30 days. First Merchants has a market cap of $770.2 million and is part of the financial sector and banking industry. Shares are down 4.41% year-to-date as of the close of trading on Tuesday.

First Merchants Corporation operates as the financial holding company for First Merchants Bank, National Association that provides community banking services. The stock currently has a dividend yield of 1.5%. The company has a P/E ratio of 13.5. Currently, there are 3 analysts who rate First Merchants a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRME - FREE

TheStreet Quant Ratings

rates First Merchants as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

First Merchants Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null